Get the (FBRX) Report Here
Trade with Jim Cramer 14 Days FREE
There are plenty of small-caps that have finally bounced and are now consolidating.
Negative sentiment in small-caps and biotech has become extreme and the gap-down open this morning was needed to wash out weak holders.
With breadth negative and the indexes up, here's the investing trap that could get you if you're not careful.
The rotational action is dominating the market, and that means that the individual merits of stocks don't matter.
The end of the quarter means a new round of quarterly reports is near, so it pays to keep an eye on favorite names.
Forte Biosciences is in free fall right now. Here's how I'm playing it.
The tricky part is that sector strength is shifting fast.
This is a nice-looking uptrend right now, and I see no reason to start anticipating major problems.
Here are names that I'm slowly accumulating right now.
Stocks with good charts, good fundamentals, and good stories are attracting buyers.
It's fun to watch the wild action, but it's not healthy for the overall market.
Here are some biotech and gaming names I am watching as these sectors begin to rotate.
Of 56 recent ARKK buys, only two are trading in positive territory Wednesday.
Small-caps look like they may be near the end of a two-month-long correction.
Quite a few stocks are fading right now -- not due to poor fundamentals, but due to lack of buying interest.
Study those charts and be ready to act as things develop.
Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.
While I remain quite bullish, I am trying to strategize a bit to deal with whatever might hide in the waning days of the year.
As this healthy bounce boosts the market, I'm seeing opportunities in these special purpose acquisition companies.
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login